Alison E Fohner1,2,3, Dilrini K Ranatunga1, Khanh K Thai1, Brian L Lawson1, Neil Risch4, Akinyemi Oni-Orisan4,5, Aline T Jelalian6, Allan E Rettie7, Vincent X Liu1, Catherine A Schaefer1. 1. Division of Research, Kaiser Permanente Northern California, Oakland, California. 2. Department of Epidemiology. 3. Institute of Public Health Genetics, University of Washington, Seattle, Washington. 4. Institute of Human Genetics. 5. Department of Clinical Pharmacy, University of California San Francisco, San Francisco. 6. Department of Neurology, Kaiser Permanente Northern California, Walnut Creek, California. 7. Department of Medicinal Chemistry, University of Washington, Seattle, Washington, USA.
Abstract
OBJECTIVE: To assess the impact of CYP2C9 variation on phenytoin patient response and clinician prescribing practice where genotype was unknown during treatment. METHODS: A retrospective analysis of Resource on Genetic Epidemiology Research on Adult Health and Aging cohort participants who filled a phenytoin prescription between 1996 and 2017. We used laboratory test results, medication dispensing records, and medical notes to identify associations of CYP2C9 genotype with phenytoin blood concentration, neurologic side effects, and medication dispensing patterns reflecting clinician prescribing practice and patient response. RESULTS: Among 993 participants, we identified 69% extensive, 20% high-intermediate, 10% low-intermediate, and 2% poor metabolizers based on CYP2C9 genotypes. Compared with extensive metabolizer genotype, low-intermediate/poor metabolizer genotype was associated with increased dose-adjusted phenytoin blood concentration [21.3 pg/mL, 95% confidence interval (CI): 13.6-29.0 pg/mL; P < 0.01] and increased risk of neurologic side effects (hazard ratio: 2.40, 95% CI: 1.24-4.64; P < 0.01). Decreased function CYP2C9 genotypes were associated with medication dispensing patterns indicating dose decrease, use of alternative anticonvulsants, and worse adherence, although these associations varied by treatment indication for phenytoin. CONCLUSION: CYP2C9 variation was associated with clinically meaningful differences in clinician prescribing practice and patient response, with potential implications for healthcare utilization and treatment efficacy.
OBJECTIVE: To assess the impact of CYP2C9 variation on phenytoinpatient response and clinician prescribing practice where genotype was unknown during treatment. METHODS: A retrospective analysis of Resource on Genetic Epidemiology Research on Adult Health and Aging cohort participants who filled a phenytoin prescription between 1996 and 2017. We used laboratory test results, medication dispensing records, and medical notes to identify associations of CYP2C9 genotype with phenytoin blood concentration, neurologic side effects, and medication dispensing patterns reflecting clinician prescribing practice and patient response. RESULTS: Among 993 participants, we identified 69% extensive, 20% high-intermediate, 10% low-intermediate, and 2% poor metabolizers based on CYP2C9 genotypes. Compared with extensive metabolizer genotype, low-intermediate/poor metabolizer genotype was associated with increased dose-adjusted phenytoin blood concentration [21.3 pg/mL, 95% confidence interval (CI): 13.6-29.0 pg/mL; P < 0.01] and increased risk of neurologic side effects (hazard ratio: 2.40, 95% CI: 1.24-4.64; P < 0.01). Decreased function CYP2C9 genotypes were associated with medication dispensing patterns indicating dose decrease, use of alternative anticonvulsants, and worse adherence, although these associations varied by treatment indication for phenytoin. CONCLUSION:CYP2C9 variation was associated with clinically meaningful differences in clinician prescribing practice and patient response, with potential implications for healthcare utilization and treatment efficacy.
Authors: Patricia T Illing; Julian P Vivian; Nadine L Dudek; Lyudmila Kostenko; Zhenjun Chen; Mandvi Bharadwaj; John J Miles; Lars Kjer-Nielsen; Stephanie Gras; Nicholas A Williamson; Scott R Burrows; Anthony W Purcell; Jamie Rossjohn; James McCluskey Journal: Nature Date: 2012-06-28 Impact factor: 49.962
Authors: Ying-Kit Cheung; Suk-Hang Cheng; Ernest J M Chan; Su V Lo; Margaret H L Ng; Patrick Kwan Journal: Epilepsia Date: 2013-05-20 Impact factor: 5.864
Authors: Mark N Kvale; Stephanie Hesselson; Thomas J Hoffmann; Yang Cao; David Chan; Sheryl Connell; Lisa A Croen; Brad P Dispensa; Jasmin Eshragh; Andrea Finn; Jeremy Gollub; Carlos Iribarren; Eric Jorgenson; Lawrence H Kushi; Richard Lao; Yontao Lu; Dana Ludwig; Gurpreet K Mathauda; William B McGuire; Gangwu Mei; Sunita Miles; Michael Mittman; Mohini Patil; Charles P Quesenberry; Dilrini Ranatunga; Sarah Rowell; Marianne Sadler; Lori C Sakoda; Michael Shapero; Ling Shen; Tanu Shenoy; David Smethurst; Carol P Somkin; Stephen K Van Den Eeden; Lawrence Walter; Eunice Wan; Teresa Webster; Rachel A Whitmer; Simon Wong; Chia Zau; Yiping Zhan; Catherine Schaefer; Pui-Yan Kwok; Neil Risch Journal: Genetics Date: 2015-06-19 Impact factor: 4.562
Authors: M J V Pugh; A C Van Cott; J A Cramer; J E Knoefel; M E Amuan; J Tabares; R E Ramsay; D R Berlowitz Journal: Neurology Date: 2008-05-27 Impact factor: 9.910
Authors: Alison E Fohner; Allan E Rettie; Khanh K Thai; Dilrini K Ranatunga; Brian L Lawson; Vincent X Liu; Catherine A Schaefer Journal: Clin Transl Sci Date: 2020-04-18 Impact factor: 4.689